Episode
#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field
- Podcast
- The Peter Attia Drive
- Published
- Apr 13, 2026
- Duration seconds
- 1321
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-peter-attia-drive-403612/episodes/387-ama-83-peptides-evaluating-the-science-safety-and-hype-in-a-rapidly-growing-field/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-peter-attia-drive-403612/387-ama-83-peptides-evaluating-the-science-safety-and-hype-in-a-rapidly-growing-field.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page . If you are not a subscriber, you can learn more about the subscriber benefits here . We discuss: Setting the framework for evaluat…